2017年3月8日星期三

Scientists find same proteins in aging cells and cancer cells

According to a study involving recombinant rat proteins by Queen Mary University in London, proteins have played an unknown role in aging cells, and the researchers hope that this finding will play a role in the treatment of aging and early cancer.

The organs and tissues of our bodies are made up of a large number of cells that interact to regulate the body's function and to remain healthy. However, some of the same "abnormal" cells have been found in cells of aged cells and early cancer patients.

The study captures the increasing number of "aging" cells that affect the function of the tissue. And when the aging cells fail to proliferate, they try to communicate with neighboring cells, and the route of communication is primarily to release inflammatory proteins. The study published in the study Cell Report describes the method of aging cell exchange through integrin membrane proteins which includes a highly-expressed "integrin β3" protein in the aging cells.

"This is the first time that integrin β3 has proven its role in the aging process, and this research contributes to the future treatment of early cancer and aging," the researchers said. By the way, Flarebio provides you with superior recombinant proteins including recombinant CDH2 for your research.

The protein CD151 can improves the prognosis of ovarian cancer

Ovarian cancer researchers have identified protein biomarkers that are expressed on the surface of tumor cells in highly serous ovarian cancer (the most common and lethal subtype of the disease).

The main author Mauricio Medrano, molecular biologist and researcher at the Princess Margaret Cancer Center, has published his findings in a cellar journal which also has published other studies on recombinant human proteins. The study shows that patients with a high level of biomarker CD151 had a poor prognosis reaction.

"Ovarian cancer is caused by a variety of diseases," Dr. Medrano said. By identifying the potential role of CD151 and its survival in cancer cells, we hope to develop a treatment to target it as a marker of poor prognosis to further study to acquire the potential to develop a clinical screening tool, helping to individualize cancer treatment.

The study was led by lead researcher Robert Rottapel, and the study team also includes senior scientists and professors from the Department of Medical Biophysics and Immunology at the University of Toronto.

In a laboratory experiment, the team used cell lines from 40 patient tumor samples to determine whether CD151 could contribute to the survival of highly serous ovarian cancer cell sources. The team further analyzed the population of approximately 1,000 patients to establish a high level of link between CD151 and poor prognosis.

Dr. Medrano said, "For the scientific community, our research provides a lot of new information about other possible targets, not just CD151, which may be important and can provide new ideas on how to target ovarian cancer." By the way, Flarebio offers high-quality recombinant proteins like recombinant CDH2 at competitive prices.

Scientists have discovered more in the processes of protein folding

Biophysicists at the JILA Physics Research Center at the University of Colorado, USA, have more surprisingly measured the folding of proteins and are surprised to find that their folding processes are more complex than scientists have predicted. This means that our understanding on the degree of protein is still in the fur. Protein response is far more sophisticated than we have detected in the past 17 years. Thus, more research involved in recombinant mouse proteins should be done.

The basic composition of protein molecules is the amino acid chain. Through a series of intermediate processes, like the origami, the amino acid chain is folded into a three-dimensional structure, and then having a function. Accurately describing this folding process requires the formation of all intermediate states. The latest research reveals many unknown states in the process, and the results are published in the March 3 issue of the journal Science.

Researchers are researching a membrane protein that converts light into chemical energy, called bacteriorhodopsin (BR), with a molecular weight of about 26 kD. It provides a model for cell membrane receptor proteins and also contributes to elucidating the mechanism of interaction between the receptor and the signal in the signal transduction pathway of the human body, the BR or the proton protein of the ionomer channel on the cell membrane, and the role of the proton transfer membrane, so that it can be the other ion channel protein. Finally, its photoelectric response and photochromic specific make it have broad prospects in the solar cell, artificial retina, optical information storage, neural networks, bio-chip and other fields. Therefore, BR research has attracted the attention of countless scientists in the world. However, the folding of membrane proteins is more difficult than the folding of globular proteins with relatively small size.

Tom Perkins and colleagues who led the study used the nano-scale atomic force microscope (AFM) to stretch the BR protein and measure its degree of stretch at different stretching rates (nanometers per second). The measurement method comes from JILA's previous study, a soft AFM short probe (short, soft AFM) that can quickly measure the sudden change in force during protein development and immediately feed back a signal in the middle of the protein. By further refining these AFM probes, JILA researchers can detect BR proteins at different pull rates faster (faster than 100 times) and more accurate (10 times higher accuracy).

The JILA team found that the intermediate state was not only more than expected, and that the entire folding process was only 8 microseconds (1 microsecond equal to one millionth of a second). The results explain why there is a long-standing difference between experimental data and molecular simulations. At the same time, for the molecular simulation means to provide confidence in the future study of membrane protein behavior identified a path.

The technology can also be applied to many other molecular studies such as medical, protein, and drug interactions. More specific examples, such as structural and functional studies of proteins that are similar to BR structures are associated with many human diseases and drugs. By the way, Flarebio provides you with superior recombinant proteins such as recombinant ECE1 at competitive prices.

REV-ERB can reduce LDL (LDL) cholesterol in animal models

A paper published in Biochemical Pharmacology by researchers at Saint Louis University have studied through recombinant human proteins about how nuclear receptors called REV-ERB are involved in the regulation of cholesterol metabolism. Their findings suggest that drugs targeting such nuclear receptors may be able to reduce LDL (LDL) cholesterol in animal models.

Dr. Thomas Burris, Ph.D., director of pharmacology and physiology at the University of St. Louis, said that studying the nuclear receptor signaling, the intracellular information system is the basis of many physiological processes used by the body. He identifies the natural hormones that regulate the nuclear receptors, and then synthesizes the compounds to target these receptors to develop drugs that treat the disease. REV-ERB is a nuclear receptor, a protein that plays a variety of roles. In the past, Burris has studied its role in regulating the internal clock of mammals.

Cholesterol is an essential component of the cell membrane. Atherosclerosis, plaque accumulation in the arteries, is caused by cholesterol metabolism disorders. Drugs such as statins can reduce low-density lipoprotein (LDL) cholesterol levels and atherosclerosis risk, but they are not suitable for everyone. Some patients stop medication because of side effects. Thus, additional cholesterol-lowering drugs are required. Nuclear receptors regulate basic physiological processes such as growth, development and metabolic balance in vivo. REV-ERB is a nuclear receptor that binds to a particular DNA sequence and limits the transcription of the target gene. Studies over the past decade have shown that REV-ERB plays an important role in metabolic pathways. Previous data indicate that REV-ERB lacks lipid metabolism that results in destruction; mice lacking REV-ERB expression show a significant increase in LDL and total cholesterol.

Similarly, in the previous study, Burris found a recombinant version of SR9009 called REV-ERB to reduce cytoplasmic cholesterol and triglyceride levels in animal models. In this study, Burris found that REV-ERB worked in the inhibition of several cholesterol-related enzyme genes and that pharmacological activation of REV-ERB resulted in further inhibition of these genes, which was associated with reduced cholesterol levels. These results reveal the way REV-ERB directly and indirectly regulates cholesterol and indicates that targeted REV-ERB may be an effective method for clinically suppressing LDL cholesterol levels. Flarebio offers high-quality recombinant proteins like recombinant CDH15.

2017年3月7日星期二

Certain types of immune cells in tumors may increase survival

A pilot study using recombinant rat proteins and conducted by researchers at the University of Otago shows that patients with colorectal cancer having certain types of immune cells in their tumors may increase their survival. Researchers at the Department of Microbiology and Immunology have found that people with more "T-regulated" immune cells in colorectal tumors are more likely to be disease-free and have a longer life span than those with fewer of these cells.

The study involved 32 patients with earl-stage (II) colorectal cancer. These patients received more than 5 years of follow-up: 13 patients showed cancer recurrence during this period; 19 patients showed no recurrence. These findings have been published in the International Journal Cancer Immunology, Immunotherapy.

By making use of a new tool to detect tumor and immune cells in immune cells infiltrates and measuring more complex immune cells, researchers investigated which type of immune response is associated with patient survival. The researchers found that although Immunoscore was superior to the current staging in assessing patient survival, the addition of "effectally Treg" immune cells made it better to survive. Kirsten Ward-Hartstonge, co-author and doctoral scholar of the study, said, " The findings suggest that it is possible to detect the immune response of patients with colorectal cancer to estimate which patients may be suffering from cancer and therefore should be given additional treatment. This information can be used to customize existing treatment programs to target people who really need them, rather than taking more blankets."

"About a quarter of patients who are currently considered ‘low risk’ will use the current staging method to potentially develop the disease again," Miss Ward-Hartstonge said. These patients usually do not receive chemotherapy or radiotherapy because the risks and costs are considered to be more beneficial.

By detecting immune cells from individual patients and "Treg" immune cells, it may be possible to more accurately identify patients with high risk and more effective treatment. Other studies have shown that New Zealand and Australia have the highest incidence and mortality rates for colorectal cancer in the world. It is possible to more accurately identify patients with high risk and more effective treatment. Other studies have shown that New Zealand and Australia have the highest incidence and mortality rates for colorectal cancer in the world. Flarebio offers high-quality recombinant proteins of good quality such as recombinant TLR2 at good prices.

To prevent and treat liver metabolism in new method

Recently, the Nature - Medicine published the latest research results by Professor Li Hongliang research team at the Wuhan University School of Basic Medical Dean online, revealing through recombinant dog proteins for the first time that the natural immune important molecules CFLAR plays key negative regulatory role in nonalcoholic steatohepatitis (NASH) disease, further clarifying its molecular mechanism and having important clinical significance on NASH prevention and treatment.

This study is another major breakthrough in the field of liver metabolic disease research, and it provides a new insight into the understanding of the pathogenesis of NASH, which lays a theoretical foundation for the development of targeted therapy. Professor Li Hongliang told reporters, "CFLAR is an important molecule of the natural immune regulation network. After eight years of research and based on a variety of genetic engineering animal disease model and molecular biology, the team confirmed the key inhibition role of CFLAR on NASH Inflammation, fibrosis, insulin resistance and liver lipid accumulation.

Further in-depth molecular mechanism studies have shown that CFLAR improves and reverses NASH progression by inhibiting the formation of N-dimerization of ASK1 and blocking ASK1 activation. By the way, Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It offers good-quality recombinant proteins like recombinant Aoc3 for your research at reasonable prices.

2017年3月6日星期一

Researchers have found the key to molecular aging in the blood and immune systems

The team at the new University of California, San Francisco has found the key to molecular aging in the blood and immune systems, and it is expected to address chronic diseases, anemia, blood cancer and various diseases caused by infection. The study has been published in the journal Nature, which also publishes other studies on recombinant rat proteins.

The researchers said, "In addition to the normal cell waste disposal, the autophagy has influences on the orderly maintenance of hematopoietic stem cells (hsc), as well as the whole immune system resist to infection and treatment of pathogens.

The researchers found that autophagy can inhibit hepatic stellate cells so that the hepatic stellate cells with active metabolism can come back to resting and quiet state. This is a new discovery of autophagy in stem cell organisms. Inactivated autophagy has a profound effect on the blood system, leading to imbalance in some types of white blood cells. Autophagy also reduces the ability of hepatic stellate cells to regenerate.

By testing in mice, the researchers found that 70% of spleen cells in aging mice did not develop autophagy and showed a dysfunction. In addition, scientists have found many different tissue stem cells, and all the performance will be reduced with age.

"This finding provides a new perspective for anti-aging, focusing on the old hepatic stellate cells and slowing down the aging blood system. And we want to find a real ability to improve stem cells themselves and use this ability to help older people and provide them with a better immune system to resist infection by preventing the development of blood diseases. Flarebio provides recombinant proteins of good quality such as recombinant Itgb5 at reasonable prices.